Silence Therapeutics Plc Stock Today
| SLN Stock | USD 4.50 0.22 4.66% |
PerformanceVery Weak
| Odds Of DistressAverage
|
Silence Therapeutics is selling at 4.50 as of the 2nd of March 2025; that is 4.66 percent decrease since the beginning of the trading day. The stock's open price was 4.72. Silence Therapeutics has 54 percent odds of going through some form of financial distress in the next two years and has generated negative returns to investors over the last 90 days. The performance scores are derived for the period starting the 31st of January 2025 and ending today, the 2nd of March 2025. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 8th of September 2020 | Category Healthcare | Classification Health Care |
Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development of novel ribonucleic acid therapeutics in hematology, cardiovascular, and other rare and metabolic indications. Silence Therapeutics plc is headquartered in London, the United Kingdom. The company has 47.21 M outstanding shares of which 1.43 M shares are at this time shorted by investors with about 3.56 days to cover. More on Silence Therapeutics PLC
Moving against Silence Stock
Follow Valuation Options Odds of Bankruptcy
Check how we calculate scores
Silence Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| President Officer | Craig MBA | |||||||||||||||||||||||||||||||||||||||||||||
| Old Names | [Silence Therapeutics plc, STELLA VISTA TECH] | |||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Biotechnology, NASDAQ Composite, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||
Silence Therapeutics PLC (SLN) is traded on NASDAQ Exchange in USA. It is located in 72 Hammersmith Road, London, United Kingdom, W14 8TH and employs 109 people. Silence Therapeutics is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a total capitalization of 222.85 M. Silence Therapeutics PLC runs under Biotechnology sector within Health Care industry. The entity has 47.21 M outstanding shares of which 1.43 M shares are at this time shorted by investors with about 3.56 days to cover.
Silence Therapeutics PLC has about 51.56 M in cash with (67.64 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.72.
Check Silence Therapeutics Probability Of Bankruptcy
Ownership AllocationSilence Therapeutics PLC shows a total of 47.21 Million outstanding shares. Over half of Silence Therapeutics' outstanding shares are owned by institutional holders. These institutional holders are typically referred to as corporate investors that take positions in a given instrument to benefit from reduced trade commissions. Please note that no matter how many assets the company owns, if the real value of the company is less than the current market value, you may not be able to make money on it.
Check Silence Ownership Details
Silence Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Bank Of America Corp | 2024-12-31 | 499.1 K | |
| Woodline Partners Lp | 2024-12-31 | 498.7 K | |
| Parkman Healthcare Partners Llc | 2024-12-31 | 491.1 K | |
| Marshall Wace Asset Management Ltd | 2024-12-31 | 488.9 K | |
| 5am Venture Management, Llc | 2024-12-31 | 476.2 K | |
| Millennium Management Llc | 2024-12-31 | 473.6 K | |
| Citadel Advisors Llc | 2024-09-30 | 436.7 K | |
| Saturn V Capital Management Llc | 2024-12-31 | 395 K | |
| Aquilo Capital Management, Llc | 2024-12-31 | 367.2 K | |
| Tcg Crossover Management, Llc | 2024-12-31 | 3 M | |
| Siren, L.l.c. | 2024-12-31 | 2.8 M |
Silence Therapeutics Historical Income Statement
Silence Stock Against Markets
Silence Therapeutics Corporate Management
| John Strafford | Alliance Devel | Profile | |
| Rhonda Hellums | Chief Officer | Profile | |
| Eric Floyd | VP Assurance | Profile | |
| Gem Hopkins | Head Communications | Profile | |
| Gianine Esposito | Chief Officer | Profile | |
| Giles MD | Head VP | Profile | |
| Jrgen Wittendorff | VP Manufacturing | Profile |
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Silence Therapeutics PLC. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. You can also try the Commodity Directory module to find actively traded commodities issued by global exchanges.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Silence Therapeutics. If investors know Silence will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Silence Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.70) | Revenue Per Share | Quarterly Revenue Growth (0.59) | Return On Assets | Return On Equity |
The market value of Silence Therapeutics PLC is measured differently than its book value, which is the value of Silence that is recorded on the company's balance sheet. Investors also form their own opinion of Silence Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Silence Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Silence Therapeutics' market value can be influenced by many factors that don't directly affect Silence Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Silence Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Silence Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Silence Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.